Slide Show: Melanoma and Other Skin Cancers

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Phase 3 data may support the photodynamic therapy as a noninvasive treatment option for patients with superficial basal cell carcinoma.

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.

Phase 2 data also show responses with atezolizumab switch therapy in a population of patients with BRAF V600–positive melanoma.